Is the use of NuvaRing (etonogestrel/releasing intrauterine system) contraindicated in a patient with a family history of breast cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

If you have a family history of breast cancer, using the NuvaRing requires careful consideration, and alternative contraceptive options with potentially lower risk, such as progestin-only methods or non-hormonal methods, should be discussed with your healthcare provider. Generally, having a family history of breast cancer alone does not automatically disqualify you from using hormonal contraceptives like NuvaRing. However, your personal risk depends on several factors including how many close relatives had breast cancer, their age at diagnosis, and whether they carried specific genetic mutations like BRCA1 or BRCA2. Before starting NuvaRing, consult with your healthcare provider for a thorough risk assessment, as they may recommend genetic testing if your family history suggests a hereditary cancer syndrome 1.

Combined hormonal contraceptives like NuvaRing contain estrogen, which may slightly increase breast cancer risk in current users, though this risk decreases after stopping use. A study published in the American Journal of Obstetrics and Gynecology found that the recent Danish cohort study reported a 20% increased risk of breast cancer among current and recent hormonal contraception users 1. Another study published in the journal Gynecological Endocrinology found that estradiol therapy combined with certain progestogens, such as medroxyprogesterone, norethisterone, and levonorgestrel, was associated with an increased risk of breast cancer, while estradiol therapy combined with dydrogesterone and progesterone carried no risk 2.

Some key points to consider when evaluating the risk of breast cancer with NuvaRing use include:

  • The type and duration of hormonal contraceptive use
  • The presence of specific genetic mutations, such as BRCA1 or BRCA2
  • The number and age of close relatives with breast cancer
  • The results of genetic testing, if recommended by your healthcare provider Regular breast cancer screening is important regardless of your contraceptive choice if you have a significant family history. Your healthcare provider can help you weigh the benefits and risks of NuvaRing and other contraceptive options, and make an informed decision about the best choice for your individual situation 1, 2.

References

Research

Hormonal contraception and breast cancer.

American journal of obstetrics and gynecology, 2018

Research

Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.